Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY OF ORAL PF-06651600 AND PF-06700841 AS INDUCTION AND CHRONIC THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Clinical Trial Details

The purpose of this research study is to compare the effects of the investigational study drugs, PF-06651600 and PF-06700841, with placebo to find out which is better for treating UC. 

Because this is a research study, PF-06651600 and PF-06700841 will be given to you only during this research study and not after the research study is over. 

Key Eligibility: 

- Men and women 18 Years to 70 Years (Adult, Senior).
- Diagnosis of ulcerative colitis for greater than/equal to 4 months.
- Moderate to severe active ulcerative colitis.
- Inadequate response to, loss of response to, or intolerance to at least one conventional therapy for UC. 

Exclusion Criteria: 
- Pregnant or breastfeeding
- Clinical findings suggestive of Crohn's Disease 
- History of bowel surgery within 6 months 

    

Study contact by location

Upper East Side - Manhattan

Contact(s)

Fatiha Chabouni
(212) 746-5109
fac2005@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

1707018363

ClinicalTrials.gov:

NCT02958865

Status

Open to Enrollment

Age Group

Adult

Sponsor